1513 related articles for article (PubMed ID: 23697373)
21. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
22. Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.
Dieffenbacher S; Nyarangi-Dix J; Giganti F; Bonekamp D; Kesch C; Müller-Wolf MB; Schütz V; Gasch C; Hatiboglu G; Hauffe M; Stenzinger A; Duensing S; Schlemmer HP; Moore CM; Hohenfellner M; Radtke JP
Eur Urol Focus; 2021 Jan; 7(1):102-110. PubMed ID: 30878348
[TBL] [Abstract][Full Text] [Related]
23. Documenting the location of systematic transrectal ultrasound-guided prostate biopsies: correlation with multi-parametric MRI.
Turkbey B; Xu S; Kruecker J; Locklin J; Pang Y; Shah V; Bernardo M; Baccala A; Rastinehad A; Benjamin C; Merino MJ; Wood BJ; Choyke PL; Pinto PA
Cancer Imaging; 2011 Mar; 11(1):31-6. PubMed ID: 21450548
[TBL] [Abstract][Full Text] [Related]
24. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.
Jambor I; Kähkönen E; Taimen P; Merisaari H; Saunavaara J; Alanen K; Obsitnik B; Minn H; Lehotska V; Aronen HJ
J Magn Reson Imaging; 2015 May; 41(5):1394-404. PubMed ID: 24956412
[TBL] [Abstract][Full Text] [Related]
25. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.
Singh AK; Krieger A; Lattouf JB; Guion P; Grubb RL; Albert PS; Metzger G; Ullman K; Smith S; Fichtinger G; Ocak I; Choyke P; Ménard C; Coleman J
BJU Int; 2008 Jan; 101(2):181-5. PubMed ID: 17922874
[TBL] [Abstract][Full Text] [Related]
26. Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy.
Lotan Y; Haddad AQ; Costa DN; Pedrosa I; Rofsky NM; Roehrborn CG
Urol Oncol; 2015 Jun; 33(6):266.e9-16. PubMed ID: 25858102
[TBL] [Abstract][Full Text] [Related]
27. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
[TBL] [Abstract][Full Text] [Related]
28. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
29. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis.
Schoots IG; Nieboer D; Giganti F; Moore CM; Bangma CH; Roobol MJ
BJU Int; 2018 Dec; 122(6):946-958. PubMed ID: 29679430
[TBL] [Abstract][Full Text] [Related]
30. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Grutters J; Redekop K; Armstrong N; Lee K; Gloy V; Raatz H; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2013 Apr; 17(16):1-243. PubMed ID: 23611316
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Ahmed HU; El-Shater Bosaily A; Brown LC; Gabe R; Kaplan R; Parmar MK; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham AP; Oldroyd R; Parker C; Emberton M;
Lancet; 2017 Feb; 389(10071):815-822. PubMed ID: 28110982
[TBL] [Abstract][Full Text] [Related]
32. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
[TBL] [Abstract][Full Text] [Related]
33. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
[TBL] [Abstract][Full Text] [Related]
34. Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).
Panebianco V; Sciarra A; Ciccariello M; Lisi D; Bernardo S; Cattarino S; Gentile V; Passariello R
Radiol Med; 2010 Dec; 115(8):1314-29. PubMed ID: 20852963
[TBL] [Abstract][Full Text] [Related]
35. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
Dell'Oglio P; Stabile A; Soligo M; Brembilla G; Esposito A; Gandaglia G; Fossati N; Bravi CA; Dehò F; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973
[TBL] [Abstract][Full Text] [Related]
36. Correlation of multiparametric MRI with histopathological grade of peripheral zone prostate carcinoma.
Singla A; Deep N; Naik S; Mohakud S; Nayak P; Sable M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S569-S576. PubMed ID: 38384020
[TBL] [Abstract][Full Text] [Related]
37. Multiparametric MRI guidance in first-time prostate biopsies: what is the real benefit?
Acar Ö; Esen T; Çolakoğlu B; Vural M; Onay A; Sağlıcan Y; Türkbey B; Rozanes İ
Diagn Interv Radiol; 2015; 21(4):271-6. PubMed ID: 26027768
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging-targeted, 3D transrectal ultrasound-guided fusion biopsy for prostate cancer: Quantifying the impact of needle delivery error on diagnosis.
Martin PR; Cool DW; Romagnoli C; Fenster A; Ward AD
Med Phys; 2014 Jul; 41(7):073504. PubMed ID: 24989418
[TBL] [Abstract][Full Text] [Related]
39. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning.
Franiel T; Stephan C; Erbersdobler A; Dietz E; Maxeiner A; Hell N; Huppertz A; Miller K; Strecker R; Hamm B
Radiology; 2011 Apr; 259(1):162-72. PubMed ID: 21233291
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Woo S; Suh CH; Eastham JA; Zelefsky MJ; Morris MJ; Abida W; Scher HI; Sidlow R; Becker AS; Wibmer AG; Hricak H; Vargas HA
Eur Urol Oncol; 2019 Nov; 2(6):605-616. PubMed ID: 31204311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
